The strategic location of mast cells at the host-environment interface and their ability to release potent mediators of inflammation have suggested that these cells may play a pivotal role in host defense against bacterial infection. The ability of the opportunistic pathogen, Escherichia coli, to induce degranulation of mast cells obtained from the mouse peritoneum was investigated. We determined that unlike a mutant derivative deficient in the FimH subunit of the fimbriae or nonfimbriated E. coli, type 1 fimbriated E. coli induced mast cell degranulation in vitro. The magnitude of mast cell degranulation was directly proportional to the number of adherent bacteria on the cell surface in the initial period of the interaction. Using a mouse model of bacterial peritonitis, we demonstrated mast cell degranulation and histamine release by type 1 fimbriated bacteria in vivo. Furthermore, beads coated with FimH but not with FimA, the major subunit of type 1 fimbriae, evoked mast cell release of histamine in vivo in amounts comparable to that elicited by type 1 fimbriated E. coli. These studies reveal that mast cells can be degranulated by interaction with type 1 fimbriated E. coli and that FimH, the mannose-binding component of the fimbriae, is a potent mast cell stimulant. (J. Clin. Invest. 1994. 
Introduction
Bacterial infections are accompanied by a rapid and vigorous cascade of inflammatory reactions in the host. Currently, there is limited information on how this inflammatory process is initiated or which host cells are involved. One cell that has the potential to play a pivotal role in the pathogenesis of bacterial infections is the mast cell. These are a heterogeneous group of cells that are derived from hematopoietic precursors. Mast cells are preferentially localized at mucosal surfaces, skin, and around blood and lymphatic vessels, which are also common sites ofentry for pathogenic bacteria. Mast cells have the capacity to release a variety of biologically active molecules such as products of arachidonic acid oxidation, histamine, cytokines, proteases, etc. ( 1), which could potentially affect the rate and intensity of the inflammatory reactions to bacteria. Although mast cells are well known for their role in type 1 hypersensitiv-ity reactions, other functions have been suggested. Galli and Kitamura (2) have presented a comprehensive review on the role of mast cells in various biological processes. These investigators have demonstrated mast cell involvement in leukocyte infiltration, edema, and fibrin deposition in inflammation resulting from substance P and phorbol myristate acetate (3, 4) . We have previously shown the role of mast cells in modulating immune complex mediated inflammation (5) (6) (7) (8) . Other studies have implicated mast cells in a variety of inflammatory conditions such as osteo-and rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disorders ( 1) .
The ability of several species of bacteria to elicit mast cell release of histamine was investigated recently (9, 10) . Although many bacterial species displayed stimulatory capacity, the more potent activators of mast cells were bacterial species in the family Enterobactericeae (9) . Enterobacteria are noted for their surface expression of hairlike organelles of adhesion called fimbriae (or pili). One ofthe most commonly expressed fimbriae is type 1 fimbriae, which are characterized by their ability to recognize and bind D-mannose-containing compounds (I 1, 12). Type 1 fimbriae on enterobacteria, such as Escherichia coli, facilitate bacterial adherence to mannosylated residues on epithelial cells lining the various mucosal surfaces of the host, thereby enabling these organisms to establish a foothold in the host ( 1 1, 13) . We have shown that type 1 fimbriae promote bacterial binding and activation of different immunoinflammatory cells such as lymphocytes and neutrophils, evoking a variety of biological reactions in the activated cells ( 14, 15) . The determinant of adherence and host cell activation on type 1 fimbriae is a minor protein, FimH, which is located in a functionally competent configuration at the tips of each fimbrial filament (16) (17) (18) (19) .
We observed recently that type 1 fimbriae greatly facilitated the association of E. coli to bone marrow-derived mouse mast cells (20) . This interaction resulted in phagocytosis and killing of adherent bacteria by the mast cells. Mast cell bactericidal activity was associated with acidification of phagocytic vacuoles and the release oftoxic superoxide anions (20) . By using a FimH-mutant, we demonstrated that mast cell activation by type 1 fimbriated E. coli was mediated by FimH. Since the mast cells are primarily noted for their capacity to release various inflammatory mediators, we investigated in this study if mast cells were degranulated after exposure to type 1 fimbriated E. coli. Connective tissue mast cells provide a better model than bone marrow-derived cells for the study of mast cell degranulation; therefore, we used the former in these studies. Through in vitro and in vivo experiments, we showed that mast cells were degranulated upon exposure to type 1 fimbriated, but not to the FimH -mutant or nonfimbriated E. coli. Further, we showed that mast cell degranulation by type 1 fimbriated E. coli correlated at least in part with the adherence of the bacteria to the mast cell. The determinant on type 1 fimbriae responsible for mast cell degranulation and histamine release was FimH, the mannose-binding subunit. Bacterial strains and culture conditions E. coli ORN103(thr-l leu-6 thi-lA(argF-lac) U169xyl-7 ara-13 mti-2 gal-6 rpsL tonA2fhuA2 minA minB recA13 6(fimABCDEFGH) (17, 21) (23) . Plasmid pRT4 was subcloned from pSH2 and contains only thefimH gene (15) . Plasmid pJP4 encodes the E. coli type 1 fimbrial chaperone, FimC (15, 24) . The properties of each of these plasmids have been described in detail elsewhere (15, 17, (21) (22) (23) (24) (26) . The ( 14, 15) . To assess whether mast cell degranulation can be induced by type 1 fimbriated E. coli, connective tissue mast cells isolated from mouse peritoneum were exposed to a recombinant E. coli strain ORN103(pSH2) expressing cloned genes encoding for type 1 fimbriae. The degranulation of the mast cells was assessed by examining their fluorescence intensity using avidin-FITC as a probe. Avidin-FITC specifically binds to heparin, the major proteoglycan in the granules of connective tissue mast cells (28) , and thus serves as a useful indicator of mast cell degranulation. The utility ofthis technique in demonstrating mast cell degranulation has previously been shown by us in immune-complex mediated peritonitis and reverse passive Arthus reactions in mice (6, 8) . We showed that E. coli ORN 103(pSH2), when incubated with mast cells at a ratio of 50:1, triggered a significant amount of mast cell degranulation. The fluorescence intensity of both a fully granulated and partially degranulated mast cell after exposure to bacteria when viewed through an image analysis system is shown in Fig. 1 . Because totally degranulated cells could not be detected by this technique, it is noteworthy that our assessment of mast cell degranulation may be an underestimation.
To determine if type 1 fimbriae were responsible for the E. coli-mediated mast cell degranulation, we compared the fluorescence intensity of mast cells exposed to the type 1 fimbriated E. coli clone ORN103(pSH2) and to the nonfimbriated host strain E. coli ORN 103. Compared to mast cells exposed to either nonfimbriated E. coli ORN103 (175±21) or buffer ( 188±8), the fluorescence intensity of mast cells exposed to type 1 fimbriated E. coli ORN 103 (pSH2) (103±15) was significantly lower (P < 0.001 ) (Fig. 2) . Since FimH, a minor fimbrial subunit, has recently been implicated in promoting bacterial binding to mast cells (20) , we examined the degranulating capacity of a mutant strain E. coli ORN103(pUT2002) that expresses type 1 fimbriae that is deficient in FimH. Compared to the mast cell degranulation induced by E. coli expressing wild type fimbriae, the FimH-mutant evoked only minimal mast degranulation (162±14). Taken together, these results suggest that the E. coli-mediated mast cell degranulation is determined by type 1 fimbriae, and that FimH is the fimbrial subunit responsible for mast cell activation.
Relationship between adherence oftype I fimbriated E. coli and mast cell degranulation. To determine if E. coli-mediated mast cell degranulation can be correlated with the number of adherent bacteria associated with the mast cell surface, we performed a time course experiment of bacterial adherence to mast cells and mast cell degranulation. Freshly isolated mouse peritoneal mast cells were incubated with type 1 fimbriated E.
coli ORN 103(pSH2) for various lengths of time, and the bacterial adherence and corresponding mast cell degranulation was assessed. Microscopic examination ofstained mast cell preparations revealed that there is no preferential site for bacterial adherence on the mast cell surface. Although bacteria appeared randomly distributed on the mast cell, a wide range in the number of adherent bacteria per cell was observed. Examination of crystal violet-stained smears of mast cells exposed to bacteria revealed that mast cells with many adherent bacteria appeared to be fully or partially degranulated (Fig. 3 A) , whereas those with few or no adherent bacteria appeared to be replete with granules (Fig. 3 B) . The time course of bacterial adherence revealed a rapid rate of bacterial adherence in the first 30 min, followed, apparently, by a slower rate ofadherence during the next 30 min (Fig. 4 B) . It is noteworthy that in light of our recent observation that mast cells are capable of phagocytozing and degrading bacteria (20) , it is possible that the number ofadherent bacteria detectable by this assay, especially at the later time points, is only a portion of the total adherent bacteria because those bacteria that have been internalized and whose structural integrity are no longer intact will not be detected. The degree ofmast cell degranulation induced by E. coli ORN 103(pSH2) after different lengths oftime is shown in Fig.  4 A. A 10-20% loss in fluorescence intensity in the mast cells was noticed immediately upon exposure to bacteria (0 min), which was then followed by a relatively steady rate ofdegranulation over the entire 60-min incubation period (Fig. 4 A) . These results indicate that the adherence of type 1 fimbriated E. coli to mast cells followed mast cell degranulation at the early time points. At time points after 30 min, only a small increase in the number of adherent bacteria appeared to be evident, while mast cell degranulation continued incrementally. The comparison ofthe adherence ofnonfimbriated or the FimH -E. coli to mast cells and the corresponding state ofmast cell degranulation after 60 min was also examined and found to be relatively low (Fig. 4, A and B) . It is noteworthy that during 60 min of incubation with each of the bacterial strains, the viability ofthe mast cells remained unchanged (> 90% viable) as determined by the trypan blue dye exclusion test.
In vivo mast cell degranulation induced by type 1 fimbriated E. coli. Mast cell degranulation in vivo has been previously investigated in various animal models. To demonstrate the physiological relevance of our findings, we developed a mouse model of bacterial peritonitis that is closely based on a previously described model of immune complex-mediated peritonitis (7, 8) . When the degranulation of mast cells in the mouse peritoneum after 60 min of injection of 5 x 106 type 1 fimbriated E. coli ORN103(pSH2) or nonfimbriated E. coli ORN103 was compared, we determined that the mast cells exposed to type 1 fimbriated E. coli ( 106±7) were significantly lower in fluorescence intensity than cells exposed to nonfimbriated bacteria (145±12; P < 0.05) at 60 min (Fig. 5) . The marked difference in the capacity ofboth strains to cause mast cell degranulation was observed even after 15 min of exposure to bacteria (Fig. 5) . We stained and examined peritoneal mast cells after exposure to type 1 fimbriated E. coli for 15 min and determined that 54% of them were associated with at least one adherent bacteria. Interestingly, the fluorescence intensity of these mast cells was only marginally more than mast cells exposed to type 1 fimbriated E. coli for 60 min, implying that the majority of the mast cell degranulation events in vivo had occurred before the 15 min interval. These results demonstrate Figure 1 . Photographs depicting fluorescence intensity of unstimulated and stimulated mast cells when viewed through an image analysis system. Fluorescence intensity is indicated by different colors, which are not distinguishable in black and white print. Purified peritoneal mast cells were incubated with buffer (A) or E. coli ORN103(pSH2) (B) for 60 min at 370C. After which, the incubation mixture was cytospun onto a glass slide and fixed with Carnoy's fixative for 1 min. Cell smears were stained with 6.25 ,g/ml avidin-FITC for 2 h, washed with PBS, mounted in phosphate-buffered glycerol containing 30 mM triethelenediamine (pH 8.6), and examined by fluorescence microscopy. Note that the majority of mast cells exposed to the nonfimbriated ORN 103 or FimH ORN 103 (pUT2002) E. coli strains also resembled the cell shown in A. that type 1 fimbriae ofE. coli exhibit a capacity to induce mast cell degranulation in vivo, but in addition, suggest that the rate of mast cell degranulation in vivo was appreciably more rapid than in vitro.
Since type 1 fimbriae are characterized by their ability to bind mannose-containing compounds, we investigated the effect of the mannose analogue MMP in inhibiting mast cell degranulation induced by type 1 fimbriated E. coli. Mast cell degranulation was assessed after type 1 fimbriated E. coli suspended in 200 mM MMP were injected into the peritoneum of mice. A significant difference in fluorescence intensity of mast cells exposed to E. coli ORN103(pSH2) for 60 min in the presence and absence of the mannose analogue was observed. The fluorescence intensity of mast cells exposed to type 1 fimbriated E. coli in the absence of the inhibitor was 106±8, whereas in the presence ofthe inhibitor it was 141±25 (Fig. 5) . This finding indicates that the putative receptor analogue for type 1 fimbriae was capable of inhibiting mast cell degranulation in vivo. It is not known why there is a high variability in fluorescence intensity of mast cells exposed simultaneously to bacteria and the inhibitor; however, one possibility is that the high concentration of MMP was not uniformly sustainable in the mouse peritoneum for the entire duration of the experiment. We used the well-known mast cell activator compound 48/80 to show that MMP has no inhibitory effect on mast cell degranulation per se (Fig. 5) .
FimH-mediated histamine release by mast cells in vivo. To support our morphological studies of mast cell degranulation, we examined the peritoneal fluids of mice exposed to type 1 fimbriated, FimH , and nonfimbriated E. coli for released histamine. Histamine is a prominent extracellular product of mast cell degranulation and a potent inflammatory mediator. As is evident from fimbriated E. coli ORN 103(pSH2) compared to mice injected with either the FimH-mutant E. coli ORN103(pUT2002) (55.0±29 ng; P < 0.001) or nonfimbriated E. coli ORN103 (44±30 ng; P < 0.001). These results indicate that E. coli type 1 fimbriae-mediated mast cell degranulation in vivo correlated with the presence of released histamine in the peritoneal fluid, and further, that removal of FimH from E. coli impairs its ability to trigger histamine release from mast cells.
To confirm the notion that FimH is the determinant responsible for triggering histamine release, we examined the ability of isolated FimH to induce histamine release from mast cells. We recently reported the stabilization and isolation of relatively large amounts of recombinant FimH from E. coli ( 15 release, and interestingly, the amount of histamine generated (316±16 ng) was comparable to the level generated by type 1 fimbriated E. coli ORN 103 (pSH2) (Fig. 6) . Furthermore, the presence of 200 mM MMP partially neutralized the capacity of the FimH beads to cause mast cell release of histamine ( 183±1 1; P < 0.05). As an additional control for the specificity of the FimH-mediated reaction, we tested the ability of inert beads coated with FimA, the major subunit of type 1 fimbriae, to elicit histamine release. The amount ofhistamine released in the mouse peritoneum by the injection ofisolated FimA (43±9 Fig. 1 . To determine the inhibitory effect of MMP on mast cell degranulation, E. coli ORN103(pSH2) or compound 48/80 were injected into the mouse peritoneum in the presence of 200 mM MMP. The fluorescence intensity of 50-100 mast cells/mouse was evaluated and is expressed in arbitrary units. The data represent mean±SEM, n = three to five mice. *P < 0.05 compared to control and E. coli ORN103 at the corresponding time point. ng) was minimal and comparable to the amount released when the FimH-mutant E. coli ORN103(pUT2002) was used as the stimulant.
We also compared the nature ofthe inflammatory response induced in mice by the injection of FimH beads with the response evoked by type 1 fimbriated E. coli by examining the composition of the cell population in the peritoneal lavage of the two groups of mice 60 min after challenge. The percent ratio ofmast cells/neutrophils/monocytes and lymphocytes in the peritoneum of mice injected with FimH beads was 4±1: 17±5: 79±6, respectively, while this ratio in mice injected with type 1 fimbriated E. coli was 7±1: 15±1: 78±2. The corresponding ratio in untreated control mice was 9±2: 7±2: 83±5. This finding suggests that both FimH and type 1 fimbriated E. coli caused a marked but comparable increase in the population of neutrophils in the peritoneal cavity.
Discussion
Although mast cells are known primarily for their role in mediating hypersensitivity reactions against various allergens through the release of inflammatory mediators, their precise functional role(s) in the host has been the subject of considerable speculation. In this study, we propose a role for mast cells in mediating inflammation against bacteria. This notion is based on our finding that mast cells have the capacity to recognize and be activated by type 1 fimbriated E. coli. A correlation was observed between bacterial adherence to mast cells and the degranulation of these cells in the initial period of the interaction, indicating that mast cell release of inflammatory mediators can be triggered by the adherence ofbacteria to its surface. rule out the effect of products of activated peritoneal macrophages and of complement activation, both of which can be generated as early as 5 min after introduction ofthe stimulating agent (41 ) . Indeed, our observation that the rate of mast cell degranulation in vivo was appreciably faster than the rate at which adherent bacteria were capable of triggering mast cell degranulation in vitro suggests that certain host factors were also contributing to mast cell degranulation. This notion is further supported by the observation that relatively fewer numbers of type 1 fimbriated bacteria were apparently required to induce mast cell degranulation in vivo than in vitro. Although no specific effort to optimize the concentration of ORN103(pSH2) required for mast cell degranulation in either the in vitro or in vivo assays was made, we have determined that a bacteria/mast cell ratio of 50:1 is required to evoke appreciable mast cell degranulation in vitro, whereas the bacteria/mast cells ratio required to achieve mast cell degranulation in vivo was estimated to be only 3:1. This estimated ratio is based on the fact that we used 5 x 106 E. coli ORN 103 (pSH2), and that the mouse peritoneum contained 3-4 X I07 cells of which -5% (1.5 X 106) were mast cells. This ratio is probably an overestimation, considering the large number of peritoneal cells other than mast cells to which the E. coli are likely to bind. Hence, it is probable that the actual number of bacteria available to directly bind mast cells in the mouse peritoneum are only a small fraction of the injected bacteria. Taken together, we suggest that direct binding of type 1 fimbriated bacteria to mast cells cause mast cell degranulation in vivo; however, other host factors may also contribute to this process.
The extensive degranulation ofmast cells in the mouse peritoneum induced by type 1 fimbriated bacteria (Fig. 5) implied a substantial release of inflammatory mediators including histamine. However, the amounts of histamine detected (Fig. 6 ) are markedly lower than expected. This observation is attributed to the rapid degradation of histamine in the body (5) . Thus, rather than reflecting the total amount of histamine released during the entire incubation period, the histamine assay represents only recently released histamine. Mast cells are a major source of histamine in the body, and FimH triggered mast cell release of histamine, in concert with other mast cell products such as leukotrienes and cytokines, is likely to significantly impact on bacterial survival at the site of inflammation. Among other effects, histamine can induce vascular permeability (41 ) and expression of the endothelial leukocyte adhesion molecule-l (42, 43) , which indirectly facilitate recruitment of neutrophils to the site ofinflammation resulting in early elimination ofthe bacteria. Thus, because oftheir capacity to recognize and bind to specific components on bacterial surfaces, their prominent presence at the host-environment interface, and their capacity to release potent mediators of inflammation such as histamine, mast cells are likely to play a crucial role in modulating host defense against pathogenic bacteria.
